Safe Analgesic and Anti-Inflammatory for ACS with Costochondritis
For a patient with acute coronary syndrome and concurrent costochondritis, avoid all NSAIDs entirely and use opioids (morphine or fentanyl) for pain relief, with acetaminophen as an adjunct for the musculoskeletal component once the cardiac pain is controlled.
Primary Pain Management Strategy
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines explicitly state that "use of nonaspirin nonsteroidal anti-inflammatory drugs should be avoided for management of suspected or known ischemia pain whenever possible" and that "use of nonsteroidal anti-inflammatory drugs is associated with increased risk of MACE in patients with and without prior cardiac disease, with no documented benefit to support routine use in patients with ACS" 1. This is a Class III: Harm recommendation from the 2014 AHA/ACC guidelines 2.
For Acute Cardiac Pain:
Opioid analgesics are the appropriate choice:
- Morphine IV: 2-4 mg, may repeat every 5-15 minutes as needed (doses up to 10 mg may be considered) 1
- Fentanyl IV: 25-50 μg, may repeat as needed (doses up to 100 μg may be considered) 1
Important caveats about opioid use:
- Use for pain resistant to maximally tolerated anti-ischemic medications (nitrates, beta-blockers)
- May delay absorption of oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), though clinical relevance remains disputed 1, 3
- Monitor closely for adverse effects including respiratory depression and hypotension
- Consider parenteral antiplatelet agents (GP IIb/IIIa inhibitors) if using morphine with oral P2Y12 therapy 3
For Costochondritis Component:
Once the ACS is stabilized and cardiac pain is controlled, acetaminophen is the safest option for the musculoskeletal pain of costochondritis. The 2011 AHA/ACCF secondary prevention guidelines recommend that "acetaminophen and nonacetylated salicylates are recommended and preferred over cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease requiring chronic analgesia" 4.
Anti-Ischemic Medications (Not Anti-Inflammatory, But Address Cardiac Pain)
These should be optimized before resorting to higher opioid doses:
Nitroglycerin:
- Sublingual: 0.3-0.4 mg every 5 minutes up to 3 doses
- IV: Start at 10 μg/min, titrate to pain relief
- Use in hemodynamically stable patients (SBP ≥90 mm Hg) 1
Beta-blockers:
- Oral therapy within first 24 hours if no signs of heart failure, low-output state, or increased shock risk 2
What NOT to Use
Absolutely contraindicated:
- All non-aspirin NSAIDs (ibuprofen, naproxen, diclofenac, etc.) - increase MACE risk 1, 2, 1
- COX-2 selective inhibitors (celecoxib) - associated with increased cardiovascular events 5
- Immediate-release nifedipine without beta-blocker 2
The research evidence confirms this: NSAIDs increase the risk specifically for non-ST-elevation ACS (OR 1.20), with higher risk at high doses (OR 1.64) and in patients with previous ischemic heart disease (OR 1.84) 6.
Clinical Algorithm
Immediate ACS management: Aspirin loading dose (162-325 mg), antiplatelet therapy, anticoagulation per guidelines 1
Pain control hierarchy:
- First: Optimize nitrates and beta-blockers
- Second: IV morphine or fentanyl for persistent pain
- Third: Once cardiac pain controlled, add acetaminophen for costochondritis
Monitor: For opioid-related delays in P2Y12 inhibitor effect if PCI planned; consider parenteral antiplatelet agents 3
Avoid: All NSAIDs throughout hospitalization and recovery period
Common Pitfall
The most critical error would be treating the costochondritis with NSAIDs because it's "just musculoskeletal pain." The presence of ACS makes all NSAIDs harmful regardless of the indication 1, 2. The inflammatory component of costochondritis must be managed with non-NSAID approaches (acetaminophen, rest, time) while the ACS takes therapeutic priority.